TY - JOUR
T1 - Myosin Vb as a tumor suppressor gene in intestinal cancer
AU - Cartón-García, Fernando
AU - Brotons, Bruno
AU - Anguita, Estefanía
AU - Dopeso, Higinio
AU - Tarragona, Jordi
AU - Nieto, Rocio
AU - García-Vidal, Elia
AU - Macaya, Irati
AU - Zagyva, Zsuzsanna
AU - Dalmau, Mariona
AU - Sánchez-Martín, Manuel
AU - van Ijzendoorn, Sven C.D.
AU - Landolfi, Stefania
AU - Hernandez-Losa, Javier
AU - Schwartz, Simo
AU - Matias-Guiu, Xavier
AU - Ramón y Cajal, Santiago
AU - Martínez-Barriocanal, Águeda
AU - Arango, Diego
N1 - Funding Information:
This study was partially funded by grants of World Cancer Research (AICR13-0245), Instituto de Salud Carlos III (PI16/00540, PI19/00993, PI22/00773), the European Regional Development Fund (AC15/00066, AC19/00095, AC20/00022) and the Spanish Association Against Cancer (AECC GCA15152966ARAN) to DA. BB is supported by “Ajuts per a la Iniciació de la Recerca” fellowship from Diputació de Lleida- Biomedical Research Institute of Lleida.
Publisher Copyright:
© 2022, The Author(s), under exclusive licence to Springer Nature Limited.
PY - 2022/12/2
Y1 - 2022/12/2
N2 - Colorectal cancer causes >900,000 deaths every year and a deeper understanding of the molecular mechanisms underlying this disease will contribute to improve its clinical management and survival. Myosin Vb (MYO5B) regulates intracellular vesicle trafficking, and inactivation of this myosin disrupts the polarization and differentiation of intestinal epithelial cells causing microvillous inclusion disease (MVID), a rare congenital disorder characterized by intractable life-threatening diarrhea. Here, we show that the loss Myosin Vb interfered with the differentiation/polarization of colorectal cancer cells. Although modulation of Myosin Vb expression did not affect the proliferation of colon cancer cells, MYO5B inactivation increased their migration, invasion, and metastatic potential. Moreover, Myo5b inactivation in an intestine-specific knockout mouse model caused a >15-fold increase in the number of azoxymethane-initiated small intestinal tumors. Consistently, reduced expression of Myosin Vb in a cohort of 155 primary colorectal tumors was associated with shorter patient survival. In conclusion, we show here that loss of Myosin Vb reduces polarization/differentiation of colon cancer cells while enhancing their metastatic potential, demonstrating a tumor suppressor function for this myosin. Moreover, reduced expression of Myosin Vb in primary tumors identifies a subset of poor prognosis colorectal cancer patients that could benefit from more aggressive therapeutic regimens.
AB - Colorectal cancer causes >900,000 deaths every year and a deeper understanding of the molecular mechanisms underlying this disease will contribute to improve its clinical management and survival. Myosin Vb (MYO5B) regulates intracellular vesicle trafficking, and inactivation of this myosin disrupts the polarization and differentiation of intestinal epithelial cells causing microvillous inclusion disease (MVID), a rare congenital disorder characterized by intractable life-threatening diarrhea. Here, we show that the loss Myosin Vb interfered with the differentiation/polarization of colorectal cancer cells. Although modulation of Myosin Vb expression did not affect the proliferation of colon cancer cells, MYO5B inactivation increased their migration, invasion, and metastatic potential. Moreover, Myo5b inactivation in an intestine-specific knockout mouse model caused a >15-fold increase in the number of azoxymethane-initiated small intestinal tumors. Consistently, reduced expression of Myosin Vb in a cohort of 155 primary colorectal tumors was associated with shorter patient survival. In conclusion, we show here that loss of Myosin Vb reduces polarization/differentiation of colon cancer cells while enhancing their metastatic potential, demonstrating a tumor suppressor function for this myosin. Moreover, reduced expression of Myosin Vb in primary tumors identifies a subset of poor prognosis colorectal cancer patients that could benefit from more aggressive therapeutic regimens.
U2 - 10.1038/s41388-022-02508-2
DO - 10.1038/s41388-022-02508-2
M3 - Article
C2 - 36316444
AN - SCOPUS:85140973970
SN - 0950-9232
VL - 41
SP - 5279
EP - 5288
JO - Oncogene
JF - Oncogene
ER -